Network gain for Glasgow firm
Collagen secures Merck distribution deal
Collagen already has a supply deal with Nasdaq-listed musculo-skeletal specialist Histogenics Corp. Last September it acquired the assets and an exclusive worldwide licence for a product used in the treatment of cartilage and bone damage. from Cambridge University spin-out Orthomimetics and Cambridge Enterprise.
Dr Stewart White, chief executive of Collagen Solutions, said: “Our agreement with Merck makes our high quality range of medical grade collagen products available to the research market.
“Researchers need to know that the material they use in the laboratory is consistent and can be scaled up without any loss of quality or change in characteristics.
“This means that they can start with material which is suitable for medical applications from the earliest stage in their research and do not have to switch suppliers when they reach commercialisation.”